Clinical trial
Staccato Alprazolam in Panic Attack
NCT00477451 · Alexza Pharmaceuticals, Inc., Other · Completed
Key facts
| NCT number | NCT00477451 |
|---|---|
| Title | Staccato Alprazolam in Panic Attack |
| Official title | Investigation of a Single Dose of Staccato™ Alprazolam for Inhalation on Doxapram-Induced Panic Attack in Patients With Panic Disorder |
| Lead sponsor | Alexza Pharmaceuticals, Inc., Other |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Treatment of Induced Panic Attack |
| Intervention type | Drug |
| Interventions | Inhaled placebo, Inhaled alprazolam 1 mg, Inhaled alprazolam 2 mg, IV doxapram |
| Enrollment | 49 |
| Start date | May 1, 2007 |
| Primary completion | Apr 1, 2008 |
| Completion | Apr 1, 2008 |
| First posted | May 23, 2007 |
| Last update posted | Jun 16, 2017 |
| Countries | United States |
At a glance
- 1–9 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: